Connect Biopharma Holdings Limited (CNTB) Financial Ratios
6 years of historical data (2019–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.40
↑+70% vs avg
5yr avg: 0.82
30Y Low0.6·High1.0
ROE
↑
-16.2%
↓+89% vs avg
5yr avg: -143.4%
30Y Low-355%·High-16%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CNTB Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Connect Biopharma Holdings Limited currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $130M | $76M | $65M | $48M | $269M | — | — |
| Enterprise Value | $51M | $-1860060 | $-40562940 | $-32155116 | $1M | — | — |
| P/E Ratio → | -8.32 | — | — | — | — | — | — |
| P/S Ratio | 4.97 | 2.93 | — | — | — | — | — |
| P/B Ratio | 1.40 | 0.83 | 0.64 | — | 0.99 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CNTB EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.07 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
CNTB Profitability
Margins and return-on-capital ratios measuring operating efficiency
Connect Biopharma Holdings Limited earns an operating margin of -86.2%. A negative ROE of -16.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | — | — | — | — |
| Operating Margin | -86.2% | -86.2% | — | — | — | — | — |
| Net Profit Margin | -60.0% | -60.0% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -16.2% | -16.2% | -58.9% | — | -355.2% | — | — |
| ROA | -13.8% | -13.8% | -39.3% | -49.7% | -89.7% | -109.2% | -44.4% |
| ROIC | -338.2% | -338.2% | — | — | -1592.2% | — | — |
| ROCE | -23.2% | -23.2% | -47.4% | -54.2% | -45.7% | -28.8% | -31.9% |
CNTB Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $78M exceeds total debt of $178000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.85 | -1.04 | — | -0.98 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -5594.41 | -14350.83 | -4708.64 | -2080.02 |
Net cash position: cash ($78M) exceeds total debt ($178000)
CNTB Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Connect Biopharma Holdings Limited's current ratio of 11.46x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 9.97x to 11.46x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 11.46 | 11.46 | 4.85 | 9.97 | 15.30 | 27.81 | 13.24 |
| Quick Ratio | 11.46 | 11.46 | 4.85 | 10.37 | 15.30 | 26.97 | 12.44 |
| Cash Ratio | 11.07 | 11.07 | 4.68 | 9.76 | 14.89 | 26.93 | 12.40 |
| Asset Turnover | — | 0.26 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 14.74 | — | — | — | — | — |
CNTB Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Connect Biopharma Holdings Limited does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | — | — |
| Shares Outstanding | — | $55M | $55M | $55M | $52M | $54M | $56M |
Peer Comparison
Compare CNTB with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CNTBYou | $130M | -8.3 | — | — | 100.0% | -86.2% | -16.2% | -338.2% | — |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 ARQT | $3B | -158.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 DAWN | $2B | -20.7 | — | — | 89.1% | -80.8% | -22.7% | -30.5% | — |
 RXST | $239M | -6.1 | — | — | 76.6% | -35.8% | -14.0% | -13.3% | — |
 INCY | $20B | 15.3 | 11.5 | 14.4 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
 PTGX | $6B | -48.2 | — | 113.4 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 RAPT | $296M | -2.3 | — | — | — | — | -77.1% | -155.7% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 VTRS | $20B | -5.8 | 248.5 | 10.5 | 35.1% | -18.6% | -21.1% | -6.6% | 108.7 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See CNTB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CNTB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CNTB vs ABBV
Side-by-side business, growth, and profitability comparison vs AbbVie Inc..
Start ComparisonCNTB — Frequently Asked Questions
Quick answers to the most common questions about buying CNTB stock.
What is Connect Biopharma Holdings Limited's P/E ratio?
Connect Biopharma Holdings Limited's current P/E ratio is -8.3x. This places it at the 50th percentile of its historical range.
What is Connect Biopharma Holdings Limited's ROE?
Connect Biopharma Holdings Limited's return on equity (ROE) is -16.2%. The historical average is -143.4%.
Is CNTB stock overvalued?
Based on historical data, Connect Biopharma Holdings Limited is trading at a P/E of -8.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Connect Biopharma Holdings Limited's profit margins?
Connect Biopharma Holdings Limited has 100.0% gross margin and -86.2% operating margin.